Mirococept

Phase III Active

A complement inhibitor potentially for the treatment of reperfusion injury.

Research Code APT-070; APT-070C

CAS No.

MK-8719

Phase I Active

A drug potentially for the treatment of progressive supranuclear palsy.

Research Code MK-8719

CAS No.

Oglufanide disodium

(Thymogen^®) Phase III Discontinued

An angiogenesis inhibitor potentially for the treatment of Kaposi's sarcoma.

Research Code IM-862

CAS No. 237068-57-4(Oglufanide disodium)  38101-59-6(Oglufanide)

Anti-LeY-CAR

Phase I Pending

A CAR T cell therapy potentially for the treatment of multiple myeloma, acute myeloid leukaemia and myelodysplastic syndrome.

Research Code Anti-LeY-CAR

CAS No.

LD22-4

Phase I Pending

An angiogenesis inhibitor potentially for the treatment of age-related macular degeneration (AMD).

Research Code LD22-4

CAS No.

Immune globulin intravenous (Human) liquid (Bio Products Laboratory)

(Gammaplex, Subgam, Subgam-VF^®) Approved

An immunoglobulin used to treat immune thrombocytopenic purpura and primary humoral immunodeficiency.

Research Code

CAS No.

Ensituximab

Phase II Active

A tumour-associated antigen (TAA) targeted antibody potentially for the treatment of colorectal cancer and pancreatic cancer.

Research Code NEO-101; NEO-102; NPC-1-C

CAS No.

Cetuximab biosimilar (Shanghai Zhangjiang Biotechnology)

Phase III Active

An epidermal growth factor receptor (EGFR) antagonist potentially for the treatment of colorectal cancer.

Research Code CMAB-009

CAS No. 205923-56-4 (Cetuximab)

HIV vaccine (Institute of Human Virology/Profectus Biosciences)

Phase I Active

An antiviral immune modulating (AIM) therapeutic potentially for the treatment of HIV infection.

Research Code IHV 001; IHV-01

CAS No.

SGM-101

Phase II Active

A CEA targeted antibody conjugated to a near-infrared fluorochrome potentially for the detection of breast cancer, gastric cancer, pancreatic cancer and rectal cancer.

Research Code SGM-101

CAS No.

MDX-1303

(Valortim^®) Phase I Active

An anthrax toxin inhibitor potentially for the treatment of anthrax.

Research Code MDX-1303; MAb-1303

CAS No.

IMM-124E

Phase II Active

A hyperimmune bovine colostrum powder potentially for the treatment of alcoholic hepatitis, non-alcoholic steatohepatitis and autistic disorder.

Research Code IMM-124E; IMM122-I

CAS No.

Alcaftadine

(Lastacaft^®) Approved

A histamine H1 receptor (HRH1) inhibitor used to prevent eye irritation.

Research Code R-89674

CAS No. 147084-10-4(Alcaftadine)

AFM-11

Phase I Active

A CD19 and CD3 targeted bispecific TandAb potentially for the treatment of non-Hodgkin's lymphoma.

Research Code AFM-11

CAS No.

AFM-13

Phase II Active

A bispecific antibody targeting FcγRIIIa (CD16a) and CD30 receptor potentially for the treatment of Hodgkin lymphoma.

Research Code AFM-13

CAS No.

Apomorphine Hydrochloride

(APO-go, Apodref, Apofin, Apokinon, Apokyn, Britaject, Ixense, Spontain, Taluvian, Uprima, Zydis apomorphine^®) Approved

A dopamine receptor agonist used to treat Parkinson's disease.

Research Code APL-130277; KW-6500; ND-0701; TAK-251; VR-004; VR-040

CAS No. 41372-20-7(Apomorphine Hydrochloride Hemihydrate)  58-00-4(Apomorphine)

Epoetin zeta

(Retacrit, Silapo ^®) Approved

A recombinant human erythropoietin used to treat anaemia.

Research Code SB-309

CAS No. 113427-24-0 (Epoetin alfa)

Adalimumab biosimilar (Coherus BioSciences)

Phase III Active

A tumor necrosis factor α (TNFα) inhibitor potentially for the treatment of plaque psoriasis.

Research Code CHS-1420

CAS No. 331731-18-1 (Adalimumab)

Etanercept biosimilar (Coherus Biosciences)

Phase III Active

A tumour necrosis factor (TNF) inhibitor potentially for the treatment of plaque psoriasis and rheumatic disorders.

Research Code BAX-2200; CHS-0214

CAS No. 185243-69-0 (Etanercept）

Anti-cMet SIMPLE Antibody

Phase I Active

A c-met inhibitor potentially for the treatment of solid tumours.

Research Code ARGX-111

CAS No.